Skip to main content

Table 6 Effect of FVBM extract, F18 bioactive compound and atorvastatin on plasma triglycerides, total cholesterol and non-HDL-cholesterol in Triton WR-1339 induced hyperlipidemic rats after 18 hours of treatment

From: Bioactivity guided fractionation and hypolipidemic property of a novel HMG-CoA reductase inhibitor from Ficus virens Ait

Group

Triglycerides

Total cholesterol

Non-HDL-cholesterol†

NC

60.45 ± 1.22*

75.86 ± 1.32

47.5 ± 1.17

HLC

240.74 ± 3.36*

361.92 ± 4.86

328.38 ± 3.6

(+298.24%)a

(+377.08%)a

(+591.32%)a

FVT-1

95.47 ± 2.69*

126.17 ± 2.8

100.24 ± 2.5

(−60.34%)a

(−65.13%)a

(−69.47%)a

FVT-2

65.42 ± 1.17*

84.25 ± 1.25

53.3 ± 1.19

(−72.82%)a

(−76.79%)a

(−83.76%)a

CT

62.7 ± 1.48*

84.5 ± 2.25

55.8 ± 1.12

(−73.95%)a

(−76.65%)a

(−83.00%)a

AT

58.6 ± 1.15*

78.23 ± 1.25

49.6 ± 1.18

(−75.65%)a

(−78.38%)a

(−81.85%)a

  1. †For the calculation of non-HDL-C, data is taken from Tables 5 and 6.
  2. *Values are mean (mg/dl) ± SD from plasma of 5 rats in each group.
  3. NC, normal control; HLC, triton induced hyperlipidemic control; FVT-1, fed 50 mg FVBM extract/ rat; FVT-2, fed 100 mg FVBM extract/ rat; CT, fed 1 mg F18 bioactive compound/ rat and AT, given 1 mg atorvastatin/rat once.
  4. Significantly different from NC at ap < 0.001.
  5. Significantly different from HLC at ap < 0.001.